LA JOLLA, Calif.--(BUSINESS WIRE)-- DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the ...
DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that DermTech management will present at the BTIG ...
LA JOLLA, Calif.--(BUSINESS WIRE)-- DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that SKIN: The ...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the ...
DermTech, Inc., the global leader in non-invasive molecular dermatology, announced today it has completed enrollment in a clinical study to assess DNA damage induced by an excimer laser and evaluate ...
San Diego, California--(Newsfile Corp. - October 27, 2023) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of DermTech, Inc. (NASDAQ: DMTK) securities between ...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it plans to release ...
DermTech, a San Diego biotechnology company that developed a noninvasive melanoma test, is reducing its workforce by 15 percent to shave off operating expenses. The company announced last week that it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback